Company: IMNN
Filing Date: 2025-03-19
Form Type: DRS
Source: 0001641172-25-000007
Chunk: 12

Company: Imunon, Inc.
Filing Date: 2025-03-19
Form: DRS
Chunk 12
---
●] shares of Common Stock (or pre-funded warrants                      
 to purchase shares of Common Stock and common warrants to purchase shares of Common Stock) on a “reasonable                                 
 best-efforts” basis at an assumed offering price of $[●] per share of Common Stock and accompanying common warrant                          
 (which was the closing price of our Common Stock on Nasdaq on [●], 2025) (or $[●] per pre-funded warrant and                                
 accompanying common warrant). The shares of Common Stock or pre-funded warrants, respectively, and common warrants are immediately          
 separable and will be issued separately in this offering, but must initially be purchased together in this offering. The common             
 warrants are exercisable beginning on the effective date of the Warrant Stockholder Approval, provided however, if the                      
 Pricing Conditions are met, the Warrant Stockholder Approval will not be required and the common warrants will be                           
 exercisable on the Initial Exercise Date, have an exercise price equal to $[●], and will expire five years from                             
 the Initial Exercise Date or the Warrant Stockholder Approval, as applicable. This prospectus also relates to the offering of               
 the shares of Common Stock issuable upon exercise of the common warrants and pre-funded warrants. For more information regarding the        
 common warrants and pre-funded warrants, you should carefully read the section titled “Description of Securities We Are                     
 Offering” in this prospectus.                                                                                                               |
| Pre-funded                                 
 warrants offered by us in this offering    |     | We                                                                                                                                          
 are also offering to each purchaser whose purchase of shares in this offering would otherwise result in the purchaser, together with        
 its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our        
 outstanding Common Stock immediately following the consummation of this offering, the opportunity to purchase, if the purchaser so chooses, 
 pre-funded warrants (each pre-funded warrant to purchase one share of our Common Stock) in lieu of shares that would otherwise result       
 in the purchaser’s beneficial ownership exceeding 4.99% of our outstanding Common Stock (or, at the election of the purchaser,              
 9.99%). The purchase price of each pre-funded warrant and accompanying common warrant will equal the price at which one share of Common     
 Stock and accompanying warrant are being sold to the public in this offering, minus $0.0001, and the exercise price of each pre-funded      
 warrant will be $0.0001 per share